{"id":45393,"date":"2025-10-31T12:27:31","date_gmt":"2025-10-31T04:27:31","guid":{"rendered":"https:\/\/flcube.com\/?p=45393"},"modified":"2025-10-31T12:27:35","modified_gmt":"2025-10-31T04:27:35","slug":"hightide-therapeutics-announces-positive-phase-iii-results-for-htd1801-in-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45393","title":{"rendered":"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes"},"content":{"rendered":"\n<p><strong>HighTide Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2511:HKG\">HKG: 2511<\/a>) today announced that its two Phase\u202fIII clinical trials, <strong>SYMPHONY\u20111 (NCT06350890)<\/strong> and <strong>SYMPHONY\u20112 (NCT06353347)<\/strong>, have successfully completed, delivering robust efficacy and safety data for the first\u2011in\u2011class oral agent <strong>HTD1801<\/strong> in patients with Type\u202f2 Diabetes Mellitus (T2DM).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-highlights\"><strong>Clinical Trial Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Design<\/th><th>Population<\/th><th>Primary Endpoint<\/th><th>Key Findings (Week\u202f52)<\/th><\/tr><\/thead><tbody><tr><td><strong>SYMPHONY\u20111<\/strong><\/td><td>Randomized, double\u2011blind, placebo\u2011controlled<\/td><td>408 adults with inadequate glycemic control after diet &amp; exercise<\/td><td>Change in HbA1c at 24\u202fweeks<\/td><td>Significant HbA1c reduction vs. placebo; durable benefit at 52\u202fweeks<\/td><\/tr><tr><td><strong>SYMPHONY\u20112<\/strong><\/td><td>Randomized, double\u2011blind, placebo\u2011controlled<\/td><td>551 adults with inadequate glycemic control after metformin<\/td><td>Change in HbA1c at 24\u202fweeks<\/td><td>Significant HbA1c reduction vs. placebo; durable benefit at 52\u202fweeks<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Open\u2011label extension (28\u202fweeks)<\/strong>: All patients received HTD1801, confirming sustained efficacy and a favorable safety profile through 52\u202fweeks.<\/li>\n\n\n\n<li><strong>Safety<\/strong>: No new safety signals; adverse events comparable to placebo.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-htd1801-a-dual-action-cardiorenal-metabolic-modulator\"><strong>HTD1801 \u2013 A Dual\u2011Action Cardiorenal\u2011Metabolic Modulator<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Mechanism<\/strong> \u2013 Activates <strong>AMPK<\/strong> while inhibiting the <strong>NLRP3 inflammasome<\/strong>, providing complementary anti\u2011inflammatory and metabolic benefits.<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class<\/strong> \u2013 The only oral agent with a dual mechanism targeting both metabolic dysregulation and inflammasome\u2011driven inflammation in CKM disease space.<\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong> \u2013 Early Phase\u202fIII data suggest HTD1801 could transform management of T2DM and reduce downstream cardiorenal complications.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\"><strong>Next Steps<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Filing<\/strong> \u2013 HighTide will prepare a New Drug Application (NDA) for the U.S. FDA and a Marketing Authorization Application (MAA) for the EMA, leveraging the 52\u2011week dataset.<\/li>\n\n\n\n<li><strong>Phase\u202fIV Planning<\/strong> \u2013 Post\u2011marketing studies will assess long\u2011term safety, cardiovascular outcomes, and real\u2011world effectiveness.<\/li>\n\n\n\n<li><strong>Commercial Strategy<\/strong> \u2013 HighTide aims to position HTD1801 as a first\u2011line or add\u2011on therapy for T2DM, with potential expansion to other CKM indications.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release includes forward\u2011looking statements that involve risks and uncertainties. Results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025103100272_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025103100272_c.\"><\/object><a id=\"wp-block-file--media-8f204d14-78fe-4632-a0e8-cfea3606a36f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025103100272_c.pdf\">2025103100272_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025103100272_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8f204d14-78fe-4632-a0e8-cfea3606a36f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase\u202fIII clinical trials, SYMPHONY\u20111 (NCT06350890)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45397,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,39,610,1309],"class_list":["post-45393","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-diabetes","tag-hightide-therapeutics","tag-hkg-2511"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase\u202fIII clinical trials, SYMPHONY\u20111 (NCT06350890) and SYMPHONY\u20112 (NCT06353347), have successfully completed, delivering robust efficacy and safety data for the first\u2011in\u2011class oral agent HTD1801 in patients with Type\u202f2 Diabetes Mellitus (T2DM).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45393\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase\u202fIII clinical trials, SYMPHONY\u20111 (NCT06350890) and SYMPHONY\u20112 (NCT06353347), have successfully completed, delivering robust efficacy and safety data for the first\u2011in\u2011class oral agent HTD1801 in patients with Type\u202f2 Diabetes Mellitus (T2DM).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45393\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T04:27:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T04:27:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3106.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes\",\"datePublished\":\"2025-10-31T04:27:31+00:00\",\"dateModified\":\"2025-10-31T04:27:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393\"},\"wordCount\":315,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3106.webp\",\"keywords\":[\"Clinical trial results\",\"Diabetes\",\"HighTide Therapeutics\",\"HKG: 2511\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45393#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45393\",\"name\":\"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3106.webp\",\"datePublished\":\"2025-10-31T04:27:31+00:00\",\"dateModified\":\"2025-10-31T04:27:35+00:00\",\"description\":\"HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase\u202fIII clinical trials, SYMPHONY\u20111 (NCT06350890) and SYMPHONY\u20112 (NCT06353347), have successfully completed, delivering robust efficacy and safety data for the first\u2011in\u2011class oral agent HTD1801 in patients with Type\u202f2 Diabetes Mellitus (T2DM).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45393\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3106.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3106.webp\",\"width\":1080,\"height\":608,\"caption\":\"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45393#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase\u202fIII clinical trials, SYMPHONY\u20111 (NCT06350890) and SYMPHONY\u20112 (NCT06353347), have successfully completed, delivering robust efficacy and safety data for the first\u2011in\u2011class oral agent HTD1801 in patients with Type\u202f2 Diabetes Mellitus (T2DM).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45393","og_locale":"en_US","og_type":"article","og_title":"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes","og_description":"HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase\u202fIII clinical trials, SYMPHONY\u20111 (NCT06350890) and SYMPHONY\u20112 (NCT06353347), have successfully completed, delivering robust efficacy and safety data for the first\u2011in\u2011class oral agent HTD1801 in patients with Type\u202f2 Diabetes Mellitus (T2DM).","og_url":"https:\/\/flcube.com\/?p=45393","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T04:27:31+00:00","article_modified_time":"2025-10-31T04:27:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3106.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45393#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45393"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes","datePublished":"2025-10-31T04:27:31+00:00","dateModified":"2025-10-31T04:27:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45393"},"wordCount":315,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45393#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3106.webp","keywords":["Clinical trial results","Diabetes","HighTide Therapeutics","HKG: 2511"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45393#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45393","url":"https:\/\/flcube.com\/?p=45393","name":"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45393#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45393#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3106.webp","datePublished":"2025-10-31T04:27:31+00:00","dateModified":"2025-10-31T04:27:35+00:00","description":"HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase\u202fIII clinical trials, SYMPHONY\u20111 (NCT06350890) and SYMPHONY\u20112 (NCT06353347), have successfully completed, delivering robust efficacy and safety data for the first\u2011in\u2011class oral agent HTD1801 in patients with Type\u202f2 Diabetes Mellitus (T2DM).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45393#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45393"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45393#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3106.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3106.webp","width":1080,"height":608,"caption":"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45393#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HighTide Therapeutics Announces Positive Phase\u202fIII Results for HTD1801 in Type\u202f2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3106.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45393"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45393\/revisions"}],"predecessor-version":[{"id":45398,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45393\/revisions\/45398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45397"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}